Wednesday, September 28, 2022
HomeBiotechnologyRevive Therapeutics Offers Replace on the Psilocybin Scientific Examine for Methamphetamine Use...

Revive Therapeutics Offers Replace on the Psilocybin Scientific Examine for Methamphetamine Use Dysfunction and Oral Psilocybin Skinny Movie Strip Program

Facebook
Twitter
Pinterest
WhatsApp

Final Up to date on September 16, 2022 by GlobeNewsWire

TORONTO, Sept. 16, 2022 (GLOBE NEWSWIRE) — Revive Therapeutics Ltd. (“Revive” or the “Firm”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences firm centered on the analysis and improvement of therapeutics for medical wants and uncommon issues, is happy to supply an replace on the Firm’s Part I/II scientific examine of oral psilocybin within the remedy of methamphetamine use dysfunction and the event of its proprietary oral psilocybin skinny movie strip product.

“We proceed to give attention to constructing a specialty psilocybin-based product pipeline to deal with psychological sickness, substance abuse and neurological issues. We intend to advance the event of our oral psilocybin skinny movie strip product for these indications. In parallel, we’re engaged on our first scientific examine evaluating oral psilocybin within the remedy of methamphetamine use dysfunction to validate its use in substance abuse indications. The scientific information from this examine shall be used to assist late-stage scientific trials with our oral psilocybin skinny movie strip product,” stated Derrick Welsh, COO of Psilocin Pharma, a division of Revive.

Oral Psilocybin for Methamphetamine Use Dysfunction

The Firm is at the moment evaluating the usage of oral psilocybin as a possible remedy for methamphetamine use dysfunction with the College of Wisconsin-Madison. Beneath an investigator-initiated IND, led by Dr.’s Christopher Nicholas and Paul Hutson, the Part I/II scientific examine (the “Examine”) to judge the protection and feasibility of psilocybin in adults with methamphetamine use dysfunction acquired each FDA and Institutional Evaluation Board approval. The Examine is being performed on the College of Wisconsin-Madison, College of Drugs and Public Well being and College of Pharmacy.

The scientific information that’s generated from the Examine will present proprietary and worthwhile data on the protection, efficacy and dosing of oral psilocybin to assist future pivotal FDA scientific research for the Firm’s proposed oral psilocybin skinny movie strip product. As well as, the Firm could have unique entry to key mental property from this examine to assist improvement, regulatory and business initiatives.

Oral Psilocybin Skinny Movie Strip Product

The Firm has initiated the product improvement program beneath a feasibility settlement with LTS Lohmann Therapie-Systeme AG, a pacesetter in pharmaceutical oral skinny movies, to develop and manufacture a proprietary oral psilocybin skinny movie strip product for psychological sickness, substance abuse and neurological issues. Prototypes of the oral psilocybin skinny movie strip product have been developed and are being optimized to be used in upcoming IND-enabling research. The Firm expects to conduct a first-in-human scientific examine in 2023.

About Revive Therapeutics Ltd.

Revive is a life sciences firm centered on the analysis and improvement of therapeutics for infectious ailments and uncommon issues, and it’s prioritizing drug improvement efforts to reap the benefits of a number of regulatory incentives awarded by the FDA comparable to Orphan Drug, Quick Monitor, Breakthrough Remedy and Uncommon Pediatric Illness designations. Presently, the Firm is exploring the usage of Bucillamine for the potential remedy of infectious ailments, with an preliminary give attention to extreme influenza and COVID-19. With its acquisition of Psilocin Pharma Corp., Revive is advancing the event of Psilocybin-based therapeutics in numerous ailments and issues. Revive’s cannabinoid pharmaceutical portfolio focuses on uncommon inflammatory ailments and the corporate was granted FDA orphan drug standing designation for the usage of Cannabidiol (CBD) to deal with autoimmune hepatitis (liver illness) and to deal with ischemia and reperfusion damage from organ transplantation. For extra data, go to www.ReviveThera.com.

For extra data, please contact:

Michael FrankChief Govt OfficerRevive Therapeutics Ltd.Tel: 1 888 901 0036Email: mfrank@revivethera.comWebsite: www.revivethera.com

Neither the Canadian Securities Trade nor its Regulation Providers Supplier has reviewed or accepts duty for the adequacy or accuracy of this launch.

Cautionary Assertion

This press launch incorporates ‘forward-looking data’ throughout the which means of relevant Canadian securities laws. These statements relate to future occasions or future efficiency. Using any of the phrases “may”, “intend”, “anticipate”, “imagine”, “will”, “projected”, “estimated” and related expressions and statements referring to issues that aren’t historic info are supposed to establish forward-looking data and are primarily based on Revive’s present perception or assumptions as to the result and timing of such future occasions. Ahead trying data on this press launch contains data with respect to the the Firm’s cannabinoids, psychedelics and infectious ailments applications. Ahead-looking data relies on cheap assumptions which have been made by Revive on the date of the knowledge and is topic to recognized and unknown dangers, uncertainties, and different elements that will trigger precise outcomes or occasions to vary materially from these anticipated within the forward-looking data. Given these dangers, uncertainties and assumptions, you shouldn’t unduly depend on these forward-looking statements. The forward-looking data contained on this press launch is made as of the date hereof, and Revive will not be obligated to replace or revise any forward-looking data, whether or not on account of new data, future occasions or in any other case, besides as required by relevant securities legal guidelines. The foregoing statements expressly qualify any forward-looking data contained herein. Reference is made to the chance elements disclosed beneath the heading “Danger Elements” within the Firm’s annual MD&A for the fiscal yr ended June 30, 2021, which has been filed on SEDAR and is accessible beneath the Firm’s profile at www.sedar.com.

Facebook
Twitter
Pinterest
WhatsApp
RELATED ARTICLES

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Most Popular

Recent Comments